Cynapsus Therapeutics and MonoSol Rx Announce Global IP

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cynapsus Therapeutics and MonoSol Rx Announce Global IP Licensing Agreement

TORONTO, ONTARIO and WARREN, NEW JERSEY--(Marketwired - April 4, 2016) - Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (NASDAQ:CYNA)(TSX:CTH), and MonoSol Rx LLC ("MonoSol Rx") today announced that they have signed a global licensing agreement for certain intellectual property ("IP") including existing patents, patent applications, and future patents and patent applications covering all oral films containing apomorphine for the treatment of OFF episodes in Parkinson's disease ("PD") patients.

Cynapsus, the developer of APL-130277, a "turning ON" medication containing apomorphine in a fast-acting, easy-to-use, sublingual thin film for all types of OFF episodes associated with PD, holds global commercialization rights for APL-130277. Cynapsus also has a substantial patent portfolio, including issued and pending patent applications in the United States and certain other jurisdictions, covering APL-130277 and its use in the treatment of PD. MonoSol Rx has key issued industry-leading patents and pending patent applications as well as significant expertise and know-how in film technology which together with the Cynapsus' IP, creates a significant patent portfolio further strengthening APL-130277 commercial protection.

Under the license agreement, MonoSol Rx will receive up front and contingent milestone payments and single-digit royalty payments on net sales of APL-130277.

"We are delighted to have signed the agreement with MonoSol Rx for their intellectual property portfolio covering pharmaceutical films which will broaden our IP protection for APL-130277 as we move closer to commercialization. Cynapsus aims to provide patients suffering with PD a patient-friendly way to treat their often debilitating OFF episodes," said Anthony Giovinazzo, President and CEO of Cynapsus. "We continue to focus on completing our Phase 3 clinical trials and filing our NDA with the FDA near the end of 2016 or in early 2017."

Keith J. Kendall, CEO of MonoSol Rx, commented, "MonoSol Rx has the world's leading portfolio of intellectual property and knowhow relating to film applications in the pharmaceutical industry. We are very pleased to license our technology to Cynapsus. For MonoSol Rx this is recognition for the value of the capabilities and differentiation that PharmFilm® represents for patients and partners. Entering into this licensing agreement with Cynapsus benefits both parties and we are happy to be aligned with Cynapsus in providing PD patients with more convenient and effective therapies."

About Cynapsus

Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. The Company has successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a "turning ON" medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit an NDA near the end of 2016 or in early 2017. For additional company information, please visit our website www.cynapsus.ca .

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products, new molecular entities, and combination products. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products - Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com . More information about PharmFilm can be found at www.pharmfilm.com .

Cynapsus Forward-Looking Statements

This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, the Company's expectation for filing an NDA near the end of 2016 or in early 2017; expectations regarding the Company's clinical and regulatory activities, including without limitation, the anticipated timing and completion of clinical studies; and beliefs regarding the Company's IP protection for APL-130277. These forward-looking statements include information about possible or assumed future results of the Company's business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company's current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption "Risk Factors" in the Company's Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on March 9, 2016, as amended by Amendment No. 1 to Form 10-K/A filed with the SEC on March 18, 2016, and its other filings and reports in the United States with the SEC available on the SEC's web site at www.sec.gov , and in Canada with the various Canadian securities regulators, which are available online at www.sedar.com . Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law.

Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.

Cynapsus Kristen Galfetti Vice President Investor Relations (416) 703-2449 x246 kgalfetti@cynapsus.ca Media Contact: Matt Middleman Russo Partners LLC (212) 845-4272 matt.middleman@russopartnersllc.com MonoSol Rx Investor Contact: Lee Roth, Vice President The Ruth Group (646) 536-7000 lroth@theruthgroup.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 29

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 213

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 99

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 141

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
BioArctic's Q3 Call Puts Leqembi Economics Under Watch

Updated Category News Views 32

One Date, Several Unanswered Questions November 25 lands with an unusually clean checklist for BioArctic watchers: results arrive at 8:00 a.m. CET, then management takes the floor at 9:30 a.m. CET. That is the whole immediate event, and it matters because this is not a company investors can sensibly judge by a single headline or a vague promise about neuroscience....

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 22

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 149

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 121

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading

Top 5 Most Recently Viewed Articles

Streamlined Shipping Solutions for UK Businesses by Wix.com

Updated Category News Views 279

Enhancing Shipping for UK Businesses with Wix.com Wix.com Ltd. (NASDAQ: WIX) has taken a significant step forward in supporting UK businesses by integrating Royal Mail within its innovative Wix Shipping platform. This breakthrough means that merchants can now easily transition from traditional, manual shipping processes to a fully automated system, streamlining their...

Continue Reading
FullFlex.Agency Innovation: AI Solutions for Business Growth

Updated Category News Views 147

FullFlex.Agency Unleashes Innovative Marketing Solutions FullFlex.Agency is celebrating its continued success as it enters the fourth quarter of its second year. This dynamic organization, known for its robust AI-powered marketing solutions and transparent pricing structures, emphasizes its commitment to helping businesses thrive across various sectors. Expansion of...

Continue Reading
NexBank Achieves Recognition as Leading Mortgage Lender

Updated Category News Views 207

NexBank: A Consistent Leader in Mortgage Lending NexBank has once again made headlines by being recognized as one of the top mortgage lenders in the nation for the fourth consecutive year. This achievement underscores the bank's ongoing commitment to excellence in the mortgage industry. The latest rankings show that NexBank secured the 12th position for Correspondent...

Continue Reading
First Mining Gold Corp. Strengthens Position with First Majestic

Updated Category News Views 173

Key Agreement Enhancements Between First Mining Gold and First Majestic First Mining Gold Corp. (TSX: FF) has announced an important agreement with First Majestic Silver Corp. that is expected to positively impact its financial position and operational strategy. This mutually beneficial arrangement revises the parameters of the existing silver purchase agreement,...

Continue Reading
Expert Weighs In: College Apps Need Strategy, Not Count

Updated Category News Views 38

A Lesson for College-Bound Families When the question comes up about college applications, you expect to hear numbers thrown around like eight, twelve, or even twenty. But the idea that there's some magic number to crack the admissions code? It just doesn't hold water. Instead, it's all about the risk baked into your list of schools. That's where HelloCollege's recent...

Continue Reading